{"gene":"NOS1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1998,"finding":"MnSOD is enriched in nNOS neurons and is required for their resistance to NMDA-mediated neurotoxicity; antisense knockdown of MnSOD renders nNOS neurons susceptible to NMDA toxicity, and adenoviral MnSOD transfer restores resistance in MnSOD-/- cultures.","method":"Antisense knockdown, adenoviral gene transfer, cortical neuron cultures, MnSOD-/- mice","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (antisense, adenoviral OE, KO mice) replicated across cell lines and primary cultures in one study","pmids":["9482791"],"is_preprint":false},{"year":2012,"finding":"FMRP activates translation of NOS1 in the developing human neocortex by interacting with coding-region binding motifs on human NOS1 mRNA (absent from mouse Nos1 mRNA); NOS1 protein is severely reduced in developing human FXS brain but not in FMRP-deficient mice.","method":"Co-immunoprecipitation, polyribosome fractionation, postmortem human tissue, FMRP-KO mouse tissue","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, species-comparative biochemistry, human postmortem validation, single rigorous study with multiple orthogonal methods","pmids":["22579290"],"is_preprint":false},{"year":2013,"finding":"Excitotoxic stimulation recruits NOS1AP to nNOS in cortical neurons; NOS1AP interacts with p38MAPK-activating kinase MKK3, and competing with the nNOS–NOS1AP PDZ interaction reduces p38MAPK activation and subsequent neuronal death. A cell-permeable competing peptide doubled surviving tissue in a neonatal rat hypoxia-ischemia model.","method":"Co-IP, siRNA knockdown, cell-permeable competing peptide, rat cortical neuron culture, in vivo neonatal HI model","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, siRNA KD, peptide competition in vitro and in vivo, multiple orthogonal methods in one study","pmids":["23658158"],"is_preprint":false},{"year":2019,"finding":"NOS1 S-nitrosylates HDAC2 at Cys262/Cys274, reducing HDAC2 binding to STAT1, impairing HDAC2 recruitment to ISG promoters, decreasing H4K16 deacetylation, and suppressing interferon-stimulated gene expression to promote melanoma immune escape and lung metastasis.","method":"Biotin-switch S-nitrosylation assay, Co-IP, ChIP-qPCR, luciferase reporter, HDAC2-C262A/C274A site mutant, xenograft mouse model, flow cytometry","journal":"Journal of experimental & clinical cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct S-nitrosylation assay, site-directed mutagenesis abolishing effect, ChIP validation, in vivo confirmation; multiple orthogonal methods","pmids":["31805977"],"is_preprint":false},{"year":2003,"finding":"NMDA receptor activation decreases nNOS phosphorylation via calcineurin- and PP1/PP2A-dependent dephosphorylation, increasing nNOS enzymatic activity (measured by nitrotyrosine accumulation) and driving neuron death in a cell-autonomous pathway.","method":"Quantitative digital microscopy, NMDA receptor antagonists, calcineurin/phosphatase inhibitors, nitrotyrosine immunostaining, TUNEL assay in rat cortical neurons","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with multiple inhibitors and two independent readouts (nitrotyrosine, TUNEL); single lab","pmids":["14643384"],"is_preprint":false},{"year":2014,"finding":"Augmenting nNOS–CAPON interaction in mouse hippocampus causes anxiogenic behavior; disrupting it produces anxiolytic effects. The anxiogenic mechanism involves Dexras1 S-nitrosylation and downstream ERK signaling. Small-molecule blockers of nNOS–CAPON binding recapitulate the anxiolytic effect.","method":"Viral overexpression, competing peptides (Tat-CAPON-12C), small-molecule binding blockers, behavioral assays (chronic mild stress model), co-IP, western blot","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic OE/disruption, peptide competition, small-molecule validation, in vivo behavioral and molecular readouts, multiple orthogonal approaches","pmids":["25129479"],"is_preprint":false},{"year":2018,"finding":"nNOS-induced nitration of tyrosine 816 on TRKB inhibits TRKB phosphorylation and PLCγ1 binding, triggers clathrin-dependent TRKB endocytosis via AP-2, and promotes lysosomal TRKB degradation, constituting a molecular brake on neuronal plasticity. Chronic nNOS inhibition in vivo reduced TRKB nitration and promoted ocular dominance plasticity.","method":"In vitro nitration assays, site-specific mutagenesis (Y816), co-IP, endocytosis assays, nNOS inhibitor in vivo, monocular deprivation plasticity paradigm","journal":"Progress in neurobiology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct post-translational modification demonstrated, site-specific mutagenesis, functional in vivo validation, multiple orthogonal methods","pmids":["36682419"],"is_preprint":false},{"year":2017,"finding":"NOS1 S-nitrosylates PTEN, activating the AKT/mTOR pathway to inhibit excessive autophagy and promote survival of nasopharyngeal carcinoma cells; Hsp90 inhibitor geldanamycin blocks NOS1 mitochondrial translocation and reverses apoptosis resistance.","method":"Biotin-switch S-nitrosylation assay, NOS1 siRNA/pharmacological inhibition, autophagy inhibitor rescue, in vivo xenograft, western blot","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct S-nitrosylation assay, KD/KO + rescue, in vivo validation; single lab","pmids":["28243469"],"is_preprint":false},{"year":2002,"finding":"Sarcolemmal nNOS expression is dramatically reduced in sarcoglycan-deficient muscular dystrophy (alpha-, beta-, delta-, gamma-sarcoglycan mutations) even when dystrophin and syntrophin are present, demonstrating that the intact sarcoglycan-sarcospan complex is required to maintain nNOS at the sarcolemma.","method":"Western blot, immunofluorescence in animal models and patient biopsy tissue","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — protein localization by fractionation and immunostaining in multiple animal models and human tissue; single lab, two orthogonal methods","pmids":["12409321"],"is_preprint":false},{"year":2006,"finding":"Biglycan, an extracellular matrix molecule, regulates sarcolemmal localization of nNOS, dystrobrevin, and syntrophin; purified biglycan induces nNOS redistribution to the plasma membrane in cultured muscle cells, and biglycan protein injection into biglycan-null muscle restores sarcolemmal nNOS.","method":"Biglycan-null mouse analysis, purified biglycan addition to cultured muscle cells, intramuscular biglycan protein injection, immunofluorescence","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (KO) and gain-of-function (protein injection) with localization readout; single lab","pmids":["16807372"],"is_preprint":false},{"year":2012,"finding":"Cardiac-myocyte GTP cyclohydrolase 1 (GCH1) overexpression increases intracellular BH4 and constitutively increases NOS1 activity; NOS1 inhibition abolishes GCH1-dependent differences in ICaL density, PLB Ser16 phosphorylation, Ca2+ decay rate, and myocardial relaxation, placing NOS1 as the downstream mediator of BH4-dependent cardiac relaxation.","method":"Transgenic mouse model, NOS1 inhibition (SMTC), isolated hearts, field-stimulated cardiomyocytes, Ca2+ imaging, patch clamp","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic OE + pharmacological inhibition with multiple orthogonal functional readouts (Ca2+ handling, ICaL, PLB phosphorylation, contractility) in one rigorous study","pmids":["22798524"],"is_preprint":false},{"year":2021,"finding":"BH4-mediated nNOS activity in cardiomyocytes drives insulin-independent glucose uptake via NO/sGC/PKG-dependent increase in GLUT-1 plasmalemmal density; CRISPR/Cas9 knockout of nNOS in mGCH1-Tg mice abolishes BH4-dependent protection of LV function in diabetes.","method":"CRISPR/Cas9 nNOS KO, transgenic GCH1 overexpression, echocardiography, glucose uptake assay, HEK cell S-nitrosoglutathione treatment, 31P-MRS","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO abolishes phenotype, multiple mechanistic and functional readouts, confirmatory cell-based experiments; single rigorous study","pmids":["33494625"],"is_preprint":false},{"year":2019,"finding":"SGLT1 at the macula densa senses luminal glucose, upregulating NOS1 expression and Ser1417 phosphorylation; macula densa-specific NOS1 knockout abolishes glucose-stimulated NO production, blunting of TGF response, and GFR elevation, establishing a SGLT1-NOS1 axis in hyperglycemia-induced glomerular hyperfiltration.","method":"Macula densa-specific NOS1 knockout mice (AQP2-Cre × NOS1-flox), microperfusion, micropuncture, FITC-inulin GFR, SGLT1 inhibitor, western blot","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with multiple functional readouts (NO, TGF, GFR), pharmacological validation, mechanistic confirmation of phosphorylation","pmids":["30867247"],"is_preprint":false},{"year":2013,"finding":"Collecting duct (CD)-specific deletion of NOS1 causes impaired natriuresis/diuresis and salt-sensitive hypertension under high-sodium diet, demonstrating that CD NOS1 is required for fluid-electrolyte homeostasis.","method":"AQP2-Cre × NOS1-flox conditional KO mice, dietary sodium challenge, urine electrolyte/NOx measurement, telemetric blood pressure","journal":"Hypertension","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with multiple functional readouts; single lab, rigorous in vivo approach","pmids":["23608660"],"is_preprint":false},{"year":2017,"finding":"nNOS interneurons in the nucleus accumbens core (~1% of neurons) receive mGluR5-activated glutamate spillover, produce NO, and drive matrix metalloproteinase (MMP-2/9) activation and transient synaptic potentiation (AMPA current increase) in MSNs, thereby mediating cue-induced cocaine relapse.","method":"NO-sensitive electrodes, chemogenetic (DREADD) activation/silencing of nNOS interneurons, transgenic caspase ablation, MMP assay, whole-cell electrophysiology, rodent self-administration/reinstatement model","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific chemogenetics, selective ablation, electrophysiology, electrochemistry; multiple orthogonal methods in one study","pmids":["28123012"],"is_preprint":false},{"year":2018,"finding":"Contextual fear extinction induces a shift from PSD-95–nNOS to PSD-95–TrkB association in dorsal hippocampus (CA3); disrupting PSD-95–nNOS coupling in dorsal CA3 upregulates ERK phosphorylation and BDNF, promotes BDNF–TrkB–PSD-95 association, and enhances fear extinction.","method":"Co-immunoprecipitation, western blot, stereotaxic nNOS–PSD-95 disruptor peptide injection, behavioral fear conditioning/extinction paradigm","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing complex shift, peptide disruption with defined molecular and behavioral readouts; single lab","pmids":["30143658"],"is_preprint":false},{"year":2020,"finding":"Disrupting the nNOS–PSD-95 interaction with ZL006 inhibits nNOS-PSD95 binding, reduces p38 MAPK activation and apoptotic marker expression (active caspase-3, PARP-1), and improves neurological, sensorimotor, and cognitive outcomes after traumatic brain injury in mice.","method":"Co-IP, cortical neuronal cultures (glutamate excitotoxicity), mouse CCI model, TUNEL/phospho-p38 immunostaining, western blot, behavioral tests","journal":"Cerebral cortex","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirmation of target engagement, pharmacological disruption with multiple mechanistic and functional readouts; single lab","pmids":["31989159"],"is_preprint":false},{"year":2018,"finding":"nNOS–NOS1AP interaction is required for excitotoxic p38 MAPK signaling and neuropathic pain; a peptide inhibitor (TAT-GESV) disrupts nNOS–NOS1AP binding (but not nNOS–PSD95), blocks glutamate/glycine-induced neurotoxicity in cortical neurons, and suppresses paclitaxel- and nerve-injury-induced allodynia via blockade of p53-Ser15 phosphorylation downstream of p38 MAPK.","method":"In vitro binding assay, cortical neuron excitotoxicity, intrathecal peptide delivery, behavioral allodynia testing, western blot (phospho-p53)","journal":"Pain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding disruption confirmed, in vivo functional validation with mechanistic readout; single lab","pmids":["29319606"],"is_preprint":false},{"year":2018,"finding":"Disrupting PSD-95–nNOS interaction with ZL006 blocks hemorrhage-induced increase in PSD-95–nNOS binding and membrane translocation of nNOS in thalamic neurons, alleviating thalamic pain hypersensitivity when given before (but not after) hemorrhage.","method":"Co-IP, western blot, stereotaxic collagenase thalamic hemorrhage model, ZL006 systemic treatment, behavioral pain testing","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirmation, pharmacological disruption with molecular (membrane translocation) and behavioral readouts; single lab","pmids":["30193808"],"is_preprint":false},{"year":2018,"finding":"nNOS–CAPON interaction is increased by Aβ treatment in vitro and in APP/PS1 mouse hippocampus; blocking nNOS–CAPON interaction rescues memory and dendritic impairments in 4-month-old APP/PS1 mice. Downstream mechanism involves S-nitrosylation of Dexras1 and inhibition of ERK–CREB–BDNF pathway.","method":"Co-IP, APP/PS1 transgenic mice, nNOS–CAPON competing peptides, behavioral memory tests, dendritic spine morphology, western blot","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in vivo genetic/pharmacological disruption, multiple functional readouts; single lab","pmids":["29577585"],"is_preprint":false},{"year":2022,"finding":"Fluoxetine prevents chronic stress-induced nNOS–CAPON upregulation and coupling in the dentate gyrus; 5-HT1AR activation (by 8-OH-DPAT or elevated 5-HT) decreases nNOS–CAPON binding, and augmenting nNOS–CAPON binding neutralizes fluoxetine/5-HT1AR-induced synaptic plasticity (spine density, BDNF, ERK/CREB/synapsin phosphorylation) and anxiolytic/antidepressant effects.","method":"Co-IP, viral overexpression/competition constructs, 5-HT1AR agonist/antagonist pharmacology, CMS and CORT mouse models, dendritic spine analysis, behavioral tests","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, pharmacological and genetic modulation with multiple molecular and behavioral readouts; single lab","pmids":["35664081"],"is_preprint":false},{"year":2021,"finding":"NOS1AP SNPs (rs16847548, rs4657139) associated with arrhythmia risk reduce NOS1 expression and co-localization with NOS1AP in hiPSC-CMs from symptomatic LQT1 patients. NOS1 inhibition in guinea pig cardiomyocytes prolongs APD, enhances ICaL and INaL, slows Ca2+ decay, and induces delayed afterdepolarizations, establishing that NOS1AP SNPs cause NOS1 loss of function contributing to arrhythmogenesis.","method":"hiPSC-CMs from LQT1 patients with distinct NOS1AP genotypes, guinea pig cardiomyocyte NOS1 inhibition (SMTC, L-VNIO), action-potential clamp, patch clamp, Ca2+ fluorimetry","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — patient-derived hiPSC-CMs paired with pharmacological model, multiple electrophysiological and Ca2+ handling readouts; mechanistically rigorous single study","pmids":["32061134"],"is_preprint":false},{"year":2018,"finding":"Unloading-induced redistribution of active nNOS from the sarcolemma to the sarcoplasm precedes myofiber atrophy and depends on mitochondrial-derived oxidant species; displaced nNOS activity drives FoxO3 nuclear translocation to initiate muscle atrophy. In vivo inhibition of nNOS before and during unloading prevents FoxO3 nuclear accumulation.","method":"Human bed-rest biopsies, rat unloading model, NADPH-diaphorase histochemistry, immunofluorescence, mitochondrial superoxide measurement, tropomyosin disulfide analysis, FoxO3 nuclear localization assay, in vivo nNOS inhibition","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human and rodent models, multiple orthogonal methods (histochemistry, fractionation, oxidative stress markers, nuclear localization), pharmacological validation; single rigorous study","pmids":["30066461"],"is_preprint":false},{"year":2005,"finding":"Adenoviral nNOS gene transfer into the cardiac vagus increases nNOS protein expression selectively in the right vagus within 9 hours and enhances baroreflex sensitivity and heart rate responses to right vagal stimulation in pigs, demonstrating NOS1-dependent facilitation of cardiac vagal neurotransmission in vivo.","method":"Adenoviral nNOS gene transfer in vivo (pig), western blot, baroreflex/vagal stimulation electrophysiology","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain-of-function with molecular and functional readouts; single lab, large-animal model","pmids":["15893765"],"is_preprint":false},{"year":2017,"finding":"nNOS-derived NO facilitates Fos–Jun dimerization (AP-1) driving IL-12 and IL-23 expression in LPS-stimulated macrophages (TLR4-NOS1-AP1 axis); NOS1 inhibition switches AP-1 composition to ATF2–Jun, converting macrophages from IL-12high/IL-23high/IL-10low (M1) to IL-10high (M2) phenotype.","method":"Pharmacological NOS1 inhibition (TRIM), LPS-stimulated Raw 264.7 and THP1 macrophages, dimerization assays, cytokine measurement","journal":"Inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological loss-of-function with defined molecular mechanism (AP-1 subunit switching) and cytokine readouts; single lab","pmids":["28013342"],"is_preprint":false},{"year":2019,"finding":"nNOS is present in mitochondria of colon cancer cells; mitochondrial NOS1 suppresses mitochondrial superoxide and cisplatin-induced apoptosis by enhancing SIRT3 activity (mtNOS1-SIRT3-SOD2 axis). Hsp90 inhibitor geldanamycin blocks NOS1 mitochondrial translocation and reverses apoptosis resistance.","method":"Subcellular fractionation, stable NOS1 overexpression, geldanamycin treatment, SIRT3 activity assay, mitochondrial superoxide measurement, flow cytometry apoptosis assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation demonstrating mitochondrial localization, functional link via Hsp90 inhibition, SIRT3 activity readout; single lab","pmids":["31153640"],"is_preprint":false},{"year":2017,"finding":"nNOS splice variant nNOS-α generates ~2.3-fold more superoxide than nNOS-µ in electron-uncoupling reactions (EPR measurement) and in HEK293 cells upon calcium ionophore stimulation; nNOS-α expressing cells produce more 8-nitroguanosine-cGMP (a NO/ROS second messenger) than nNOS-µ expressing cells.","method":"Electron paramagnetic resonance (EPR), HEK293 stable transfection, calcium ionophore stimulation, immunocytochemistry for 8-nitroguanosine-cGMP","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro EPR measurement and cellular assays with two splice variants; single lab","pmids":["28126743"],"is_preprint":false},{"year":2022,"finding":"NOS1 loss-of-function mutations cause congenital hypogonadotropic hypogonadism by disrupting GnRH neuron function; NOS1 is transiently expressed by GnRH neurons in the human and mouse nose, and Nos1-deficient mice show dose-dependent defects in sexual maturation, olfaction, hearing, and cognition. Inhaled NO treatment during minipuberty rescues reproductive and behavioral phenotypes in Nos1-deficient mice.","method":"Whole-exome sequencing, in vitro NOS1 mutant activity assay (nitrite/cGMP production), Nos1-KO mouse model, pharmacological NO inhibition with critical time-window experiment, inhaled NO rescue","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — human genetics with functional validation of mutants in vitro, mouse KO phenotyping, pharmacological rescue, multiple orthogonal approaches","pmids":["36197968"],"is_preprint":false},{"year":2022,"finding":"In male mice, preoptic nNOS neurons (co-expressing ERα but not AR) show a sharp increase in Ser1412 phosphorylation at postnatal day 23 (minipuberty onset) that occurs independent of gonads; pharmacological ERα blockade during the infantile period blunts nNOS Ser1412 phosphorylation, linking extragonadal estrogen signaling through ERα to nNOS activation during minipuberty.","method":"Gonadectomy, ERα-selective pharmacological blockade, immunohistochemistry for phospho-nNOS Ser1412 and ERα/AR, nNOS-deficient mice, hormonal profiling (RIA/ELISA)","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gonadectomy + pharmacological dissection with defined molecular readout; single lab","pmids":["36470319"],"is_preprint":false},{"year":2019,"finding":"nNOS and the denitrosylase GSNOR co-localize at the sarcolemma and co-immunoprecipitate in C2C12 myotubes and mouse myofibers; GSNOR expression decreases in mouse models of muscular dystrophy, aging, and ALS, suggesting that nNOS–GSNOR interaction regulates S-nitrosylation homeostasis in skeletal muscle.","method":"Co-immunoprecipitation, immunofluorescence co-localization, C2C12 differentiation time-course, disease model muscle tissue analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP confirmed in cells and myofibers, replicated across multiple disease models; single lab","pmids":["31043586"],"is_preprint":false},{"year":2015,"finding":"After stroke (ischemia-reperfusion), nNOS activity increases with Ser1412 phosphorylation; GSNO treatment reduces nNOS Ser1412 phosphorylation and activity by inhibiting the upstream AMPK–LKB1 axis, thereby reducing peroxynitrite levels and providing neuroprotection.","method":"Rat cerebral IR model, GSNO treatment, nNOS activity assay, phospho-nNOS western blot, AMPK activator/inhibitor pharmacology","journal":"BMC neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological epistasis linking AMPK→nNOS Ser1412 phosphorylation→peroxynitrite with multiple converging inhibitors; single lab","pmids":["26174015"],"is_preprint":false},{"year":2019,"finding":"Novel long-range inhibitory nNOS-expressing hippocampal neurons (LINCs) project extrahippocampally (tenia tecta, diagonal band, retromammillary nucleus) and locally to CA1; selective optogenetic activation of LINCs strongly influences hippocampal oscillations and interregional coherence.","method":"Intersectional viral vector approach in mice, optogenetic activation, electrophysiology, anatomical tracing","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific genetic targeting with optogenetic functional readout; single lab","pmids":["31609204"],"is_preprint":false},{"year":2019,"finding":"SST+/nNOS+ cortical neuron-specific nNOS knockout mice show impaired homeostatic slow-wave (delta) activity after sleep loss and deficits in cortex-dependent recognition memory, placing NOS1 in SST interneurons as required for SWA homeostasis and cortical memory processes.","method":"Cell-type-specific Cre-mediated nNOS KO (SST-Cre × NOS1-flox), EEG/sleep recording, recognition memory behavioral testing","journal":"Sleep","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with EEG and behavioral readouts; single lab","pmids":["31328777"],"is_preprint":false},{"year":2021,"finding":"nNOS-derived NO promotes OxLDL uptake and proinflammatory cytokine expression by macrophages; NOS1 inhibition (L-NAME) suppresses OxLDL uptake and cytokine release, implicating NOS1 in foam cell formation and atherosclerosis progression.","method":"Pharmacological NOS1 inhibition, OxLDL uptake assay, cytokine ELISA, macrophage culture","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single pharmacological inhibitor approach, single lab, no genetic validation","pmids":["33501735"],"is_preprint":false},{"year":1997,"finding":"nNOS (localized at the plasma membrane of pancreatic acinar and submandibular salivary gland cells) mediates agonist-activated Ca2+ influx through generation of cGMP; nNOS inhibitor 7-NI selectively blocked bombesin-evoked but not CCK-JMV-180-evoked Ca2+ oscillations and Ca2+ influx.","method":"Pharmacological NOS inhibition (7-NI, NOS pathway inhibitors), cGMP assay, [Ca2+]i fluorimetry, western blot and immunolocalization of NOS isoforms","journal":"Cell calcium","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with isoform-selective inhibitor, immunolocalization to distinguish NOS isoforms, multiple readouts; single lab","pmids":["9330792"],"is_preprint":false},{"year":2021,"finding":"nNOS-derived NO promotes C/EBPα-dependent neutrophil differentiation through the G-CSFR–STAT3 axis; in vivo nNOS inhibition abrogates granulopoiesis (decreased BM mature and progenitor neutrophils). NOSIP (NOS inhibitory protein) expression decreases during the final stage of differentiation, correlating with augmented NO release and differentiation completion.","method":"nNOS overexpression in K562 cells, nNOS inhibitor in vivo (mice) and in vitro (human CD34+ HSPCs), surface marker/transcription factor analysis, NOSIP expression profiling, CML patient neutrophils vs healthy controls","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in multiple systems (cell line, mouse, human primary cells) with defined molecular pathway readouts; single lab","pmids":["33771575"],"is_preprint":false}],"current_model":"NOS1 (nNOS) is a Ca2+/calmodulin-activated enzyme that produces nitric oxide (NO) and, via splice-variant-dependent electron uncoupling, superoxide; its activity and subcellular localization are controlled by dephosphorylation (calcineurin/PP1/PP2A at inhibitory sites) and phosphorylation (AMPK→Ser1412 activating site), as well as by scaffolding interactions through its PDZ domain with PSD-95 (coupling it to NMDAR-mediated excitotoxic p38 MAPK–NOS1AP signaling), CAPON/Dexras1-ERK (modulating anxiety, depression, and addiction), and SERT; sarcolemmal targeting requires the intact dystrophin–sarcoglycan–syntrophin complex and biglycan; NO produced by NOS1 exerts downstream effects through S-nitrosylation of targets including HDAC2, PTEN, and TRKB (tyrosine nitration), through NO/sGC/PKG/GLUT-1-dependent cardiac glucose uptake, through MMP activation in accumbens circuits, and through cGMP-dependent Ca2+ influx regulation, collectively placing NOS1 at a nexus of neuronal excitotoxicity, synaptic plasticity, cardiac relaxation, renal sodium handling, muscle homeostasis, granulopoiesis, and reproductive neuroendocrine control."},"narrative":{"mechanistic_narrative":"NOS1 (nNOS) is a Ca2+/calmodulin-regulated nitric oxide synthase whose activity, subcellular targeting, and downstream signaling place it at a hub spanning neuronal excitotoxicity, synaptic plasticity, cardiac and renal physiology, muscle homeostasis, and neuroendocrine control [PMID:28123012, PMID:36197968]. Its catalytic output is gated by phosphorylation and cofactor supply: activating Ser1412/Ser1417 phosphorylation downstream of an AMPK–LKB1 axis and of SGLT1- and ERα-driven inputs drives NO production [PMID:30867247, PMID:36470319, PMID:26174015], while NMDA-receptor-triggered calcineurin/PP1/PP2A dephosphorylation paradoxically raises nitrotyrosine-generating activity to promote neuronal death [PMID:14643384]; tetrahydrobiopterin (BH4) availability set by GCH1 constitutively tunes activity in cardiomyocytes [PMID:22798524], and splice variant identity (nNOS-α vs -µ) determines the balance between NO and uncoupled superoxide output [PMID:28126743]. NOS1 signals through scaffold-organized protein complexes: PDZ-domain coupling to PSD-95 links it to NMDAR-driven, NOS1AP–MKK3–p38 MAPK excitotoxic and pain signaling [PMID:23658158, PMID:29319606], while its interaction with CAPON drives Dexras1 S-nitrosylation and ERK–CREB–BDNF modulation underlying anxiety, depression, and amyloid-associated memory deficits [PMID:25129479, PMID:29577585, PMID:35664081]. NO and reactive nitrogen species produced by NOS1 act on specific targets through S-nitrosylation of HDAC2 (suppressing interferon-stimulated genes for melanoma immune escape) and PTEN (activating AKT/mTOR), through tyrosine nitration of TRKB (a brake on plasticity), and through cGMP-dependent control of Ca2+ influx and GLUT-1-mediated cardiac glucose uptake [PMID:31805977, PMID:36682419, PMID:28243469, PMID:33494625, PMID:9330792]. At the sarcolemma, NOS1 localization requires the intact sarcoglycan complex and the matrix proteoglycan biglycan, and its mislocalization to the sarcoplasm drives FoxO3-dependent muscle atrophy [PMID:12409321, PMID:16807372, PMID:30066461]. NOS1 loss-of-function mutations cause congenital hypogonadotropic hypogonadism by impairing GnRH neuron function, a phenotype rescuable by inhaled NO during minipuberty [PMID:36197968].","teleology":[{"year":1998,"claim":"Established that nNOS-expressing neurons are paradoxically protected from their own NO output, identifying MnSOD as the antioxidant shield that confers excitotoxic resistance.","evidence":"Antisense knockdown and adenoviral MnSOD transfer in cortical neuron cultures and MnSOD-/- mice","pmids":["9482791"],"confidence":"High","gaps":["Does not define the molecular link between NO/superoxide flux and cell death in unprotected neurons","Does not address how MnSOD expression is restricted to nNOS neurons"]},{"year":2003,"claim":"Resolved how NMDA receptor activation upregulates NOS1 enzymatic activity, showing calcineurin- and PP1/PP2A-dependent dephosphorylation increases nitrotyrosine accumulation and drives cell-autonomous death.","evidence":"Pharmacological phosphatase/calcineurin inhibition with nitrotyrosine and TUNEL readouts in rat cortical neurons","pmids":["14643384"],"confidence":"Medium","gaps":["Specific dephosphorylated residue(s) not mapped","Single-lab pharmacological dissection without genetic confirmation"]},{"year":2013,"claim":"Defined the NOS1AP–MKK3–p38 MAPK axis as the excitotoxic effector downstream of nNOS, and demonstrated a druggable PDZ interaction by neuroprotective peptide competition in vivo.","evidence":"Reciprocal Co-IP, siRNA, cell-permeable competing peptide in cortical neurons and a neonatal rat hypoxia-ischemia model","pmids":["23658158"],"confidence":"High","gaps":["Does not establish stoichiometry of the nNOS–NOS1AP–MKK3 complex","Long-term outcomes of peptide intervention not assessed"]},{"year":2014,"claim":"Showed that the nNOS–CAPON scaffold interaction bidirectionally controls affective behavior via Dexras1 S-nitrosylation and ERK signaling, validating it as an anxiolytic/antidepressant target.","evidence":"Viral overexpression/disruption, competing peptides, small-molecule blockers, and behavioral assays in mice","pmids":["25129479"],"confidence":"High","gaps":["Brain-region specificity of the behavioral effect not fully delineated","Direct S-nitrosylation site on Dexras1 within this paradigm not mapped"]},{"year":2012,"claim":"Placed NOS1 downstream of GCH1/BH4 as the mediator of cardiac relaxation, linking cofactor supply to Ca2+ handling and contractility.","evidence":"Transgenic GCH1 overexpression with NOS1 inhibition, Ca2+ imaging, patch clamp, and contractility measurement in isolated hearts and myocytes","pmids":["22798524"],"confidence":"High","gaps":["Molecular target of NOS1-derived NO in the Ca2+-handling apparatus not identified here","Does not distinguish NO vs S-nitrosylation mechanisms"]},{"year":2017,"claim":"Demonstrated that NOS1 splice-variant identity dictates the NO-versus-superoxide balance, providing a molecular basis for context-dependent oxidative output.","evidence":"EPR measurement of electron uncoupling and 8-nitroguanosine-cGMP detection in HEK293 cells expressing nNOS-α vs nNOS-µ","pmids":["28126743"],"confidence":"Medium","gaps":["Physiological tissue contexts where each variant predominates not defined","Single-lab in vitro/cell measurements"]},{"year":2017,"claim":"Identified S-nitrosylation of PTEN and mitochondrial NOS1 translocation as a pro-survival mechanism in carcinoma cells, activating AKT/mTOR and limiting autophagy.","evidence":"Biotin-switch assay, NOS1 knockdown/inhibition with autophagy-inhibitor rescue and xenografts in nasopharyngeal carcinoma","pmids":["28243469"],"confidence":"Medium","gaps":["PTEN S-nitrosylation site(s) not mapped","Single-lab evidence for Hsp90-dependent mitochondrial translocation"]},{"year":2019,"claim":"Established NOS1-mediated S-nitrosylation of HDAC2 as an epigenetic immune-evasion mechanism, linking NO directly to interferon-stimulated gene suppression and metastasis.","evidence":"Biotin-switch, ChIP-qPCR, HDAC2-C262A/C274A mutants, and xenograft melanoma models","pmids":["31805977"],"confidence":"High","gaps":["Upstream regulation of NOS1 activity in melanoma not addressed","Generality across tumor types not tested"]},{"year":2018,"claim":"Showed NOS1-driven tyrosine nitration of TRKB Y816 functions as a molecular brake on neuronal plasticity by triggering receptor endocytosis and degradation.","evidence":"In vitro nitration assays, Y816 mutagenesis, endocytosis assays, and ocular dominance plasticity after in vivo nNOS inhibition","pmids":["36682419"],"confidence":"High","gaps":["Enzymatic mediator of tyrosine nitration (peroxynitrite vs other) not defined in vivo","Does not address reversibility of TRKB nitration"]},{"year":2018,"claim":"Extended scaffold-disruption logic across multiple CNS pathologies, showing nNOS–PSD-95 and nNOS–NOS1AP coupling drive p38 MAPK in TBI, neuropathic pain, thalamic hemorrhage pain, and that PSD-95–nNOS/TrkB complex switching governs fear extinction.","evidence":"Co-IP, disruptor peptides (ZL006, TAT-GESV) and behavioral models in mice/rats","pmids":["31989159","29319606","30193808","30143658","29577585"],"confidence":"Medium","gaps":["Mostly single-lab Co-IP plus pharmacology without genetic confirmation","Selectivity of disruptor compounds for specific PDZ interactions not exhaustively established"]},{"year":2013,"claim":"Established a renal physiological role, showing collecting-duct NOS1 is required for natriuresis and protection against salt-sensitive hypertension.","evidence":"AQP2-Cre conditional NOS1 knockout with dietary sodium challenge and telemetric blood pressure","pmids":["23608660"],"confidence":"High","gaps":["Downstream tubular targets of NOS1-derived NO not identified","Does not address NOS1 regulation in collecting duct"]},{"year":2019,"claim":"Defined the SGLT1–NOS1 axis at the macula densa, linking luminal glucose sensing through NOS1 Ser1417 phosphorylation to tubuloglomerular feedback and hyperfiltration.","evidence":"Macula densa-specific NOS1 knockout, microperfusion/micropuncture, GFR measurement, and SGLT1 inhibition","pmids":["30867247"],"confidence":"High","gaps":["Kinase mediating Ser1417 phosphorylation downstream of SGLT1 not identified","Translation to human diabetic hyperfiltration not directly tested"]},{"year":2021,"claim":"Connected NOS1 to insulin-independent cardiac glucose uptake via NO/sGC/PKG-driven GLUT-1 surface density, and to NOS1AP-genotype-dependent arrhythmogenesis through ion-channel regulation.","evidence":"CRISPR nNOS knockout in GCH1-Tg mice, glucose uptake assays, and LQT1 patient hiPSC-CMs with guinea pig cardiomyocyte electrophysiology","pmids":["33494625","32061134"],"confidence":"High","gaps":["Mechanism by which NOS1AP SNPs reduce NOS1 expression/co-localization not fully resolved","Direct ion-channel S-nitrosylation targets not mapped"]},{"year":2018,"claim":"Defined sarcolemmal NOS1 localization as a determinant of muscle homeostasis, showing the sarcoglycan complex and biglycan target NOS1 to the membrane and that its sarcoplasmic redistribution drives FoxO3-dependent atrophy.","evidence":"Sarcoglycan-deficient and biglycan-null models, biglycan protein injection, unloading models, and in vivo nNOS inhibition with FoxO3 nuclear localization readouts","pmids":["12409321","16807372","30066461","31043586"],"confidence":"High","gaps":["Mechanism translating displaced NOS1 activity into FoxO3 nuclear entry not fully mapped","Role of nNOS–GSNOR S-nitrosylation homeostasis in atrophy not causally established"]},{"year":2017,"claim":"Identified NOS1-expressing interneurons in the nucleus accumbens as drivers of MMP-dependent synaptic potentiation underlying cocaine relapse, defining a discrete circuit role.","evidence":"NO-sensitive electrodes, DREADD activation/silencing, caspase ablation, electrophysiology, and reinstatement behavior in rodents","pmids":["28123012"],"confidence":"High","gaps":["Molecular MMP substrates underlying potentiation not identified","Generalization to other reward circuits not tested"]},{"year":2021,"claim":"Extended NOS1 function to innate immunity and hematopoiesis, showing NO directs AP-1 composition for macrophage polarization and promotes C/EBPα-dependent granulopoiesis via G-CSFR–STAT3.","evidence":"Pharmacological NOS1 inhibition in macrophages and in vivo, nNOS overexpression in K562, and human CD34+ HSPC differentiation","pmids":["28013342","33771575"],"confidence":"Medium","gaps":["Direct molecular targets of NO in AP-1 subunit switching not defined","Largely single-lab pharmacological evidence"]},{"year":2022,"claim":"Established NOS1 as a human disease gene for congenital hypogonadotropic hypogonadism through GnRH neuron dysfunction, with a developmentally timed estrogen-ERα input activating NOS1 during minipuberty and inhaled NO rescuing the phenotype.","evidence":"Whole-exome sequencing with mutant activity assays, Nos1-KO phenotyping, time-window NO inhibition/rescue, and ERα-blockade with phospho-Ser1412 readouts","pmids":["36197968","36470319"],"confidence":"High","gaps":["Downstream NO targets in GnRH neurons not identified","Mechanism of extragonadal estrogen production driving ERα input not resolved"]},{"year":null,"claim":"How the diverse phosphorylation, scaffolding, splice-variant, and cofactor inputs are integrated to set NOS1's choice between NO, superoxide, and specific S-nitrosylation/nitration targets within a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking variant/cofactor state to target selection","Tissue-specific interactomes not systematically mapped","Reversibility and turnover of nitrosylation/nitration marks largely uncharacterized in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[26,27,10]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,6,7]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[34,14,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,5,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,9,22,34]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[7,25]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,12,34]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[2,14,31]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,7,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[24,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[27,21,3]}],"complexes":["dystrophin–sarcoglycan–syntrophin complex","nNOS–PSD-95–NOS1AP complex"],"partners":["PSD-95","NOS1AP","CAPON","BIGLYCAN","GSNOR","HDAC2","PTEN","TRKB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29475","full_name":"Nitric oxide synthase 1","aliases":["Constitutive NOS","NC-NOS","NOS type I","Neuronal NOS","N-NOS","nNOS","Nitric oxide synthase, brain","bNOS","Peptidyl-cysteine S-nitrosylase NOS1"],"length_aa":1434,"mass_kda":161.0,"function":"Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR","subcellular_location":"Cell membrane, sarcolemma; Cell projection, dendritic spine","url":"https://www.uniprot.org/uniprotkb/P29475/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NOS1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NOS1","total_profiled":1310},"omim":[{"mim_id":"614919","title":"NITRIC OXIDE-ASSOCIATED PROTEIN 1; NOA1","url":"https://www.omim.org/entry/614919"},{"mim_id":"612719","title":"6-@PYRUVOYL-TETRAHYDROPTERIN SYNTHASE; PTS","url":"https://www.omim.org/entry/612719"},{"mim_id":"611184","title":"PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1; PIEZO1","url":"https://www.omim.org/entry/611184"},{"mim_id":"610141","title":"QT INTERVAL, VARIATION IN","url":"https://www.omim.org/entry/610141"},{"mim_id":"608226","title":"NANOS C2HC-TYPE ZINC FINGER 1; NANOS1","url":"https://www.omim.org/entry/608226"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"skeletal muscle","ntpm":34.5},{"tissue":"tongue","ntpm":53.5}],"url":"https://www.proteinatlas.org/search/NOS1"},"hgnc":{"alias_symbol":["nNOS"],"prev_symbol":["NOS"]},"alphafold":{"accession":"P29475","domains":[{"cath_id":"2.30.42.10","chopping":"8-125","consensus_level":"high","plddt":86.279,"start":8,"end":125},{"cath_id":"3.40.50.360","chopping":"758-837_876-963","consensus_level":"high","plddt":84.8563,"start":758,"end":963},{"cath_id":"3.40.50.80","chopping":"1242-1404","consensus_level":"high","plddt":93.4709,"start":1242,"end":1404}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29475","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29475-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29475-F1-predicted_aligned_error_v6.png","plddt_mean":79.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NOS1","jax_strain_url":"https://www.jax.org/strain/search?query=NOS1"},"sequence":{"accession":"P29475","fasta_url":"https://rest.uniprot.org/uniprotkb/P29475.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29475/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29475"}},"corpus_meta":[{"pmid":"9482791","id":"PMC_9482791","title":"Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity.","date":"1998","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9482791","citation_count":210,"is_preprint":false},{"pmid":"22579290","id":"PMC_22579290","title":"Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22579290","citation_count":111,"is_preprint":false},{"pmid":"12140778","id":"PMC_12140778","title":"Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12140778","citation_count":102,"is_preprint":false},{"pmid":"25612209","id":"PMC_25612209","title":"Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders.","date":"2015","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25612209","citation_count":95,"is_preprint":false},{"pmid":"17395508","id":"PMC_17395508","title":"Differences in inflammatory pain in nNOS-, iNOS- and eNOS-deficient mice.","date":"2007","source":"European journal of pain (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17395508","citation_count":91,"is_preprint":false},{"pmid":"25129479","id":"PMC_25129479","title":"CAPON-nNOS coupling can serve as a target for developing new anxiolytics.","date":"2014","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25129479","citation_count":88,"is_preprint":false},{"pmid":"23658158","id":"PMC_23658158","title":"The nNOS-p38MAPK pathway is mediated by NOS1AP during neuronal death.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23658158","citation_count":85,"is_preprint":false},{"pmid":"30867247","id":"PMC_30867247","title":"Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia.","date":"2019","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/30867247","citation_count":83,"is_preprint":false},{"pmid":"28123012","id":"PMC_28123012","title":"Accumbens nNOS Interneurons Regulate Cocaine Relapse.","date":"2017","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28123012","citation_count":79,"is_preprint":false},{"pmid":"23608660","id":"PMC_23608660","title":"Renal collecting duct NOS1 maintains fluid-electrolyte homeostasis and blood pressure.","date":"2013","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/23608660","citation_count":74,"is_preprint":false},{"pmid":"12409321","id":"PMC_12409321","title":"Loss of sarcolemma nNOS in sarcoglycan-deficient muscle.","date":"2002","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12409321","citation_count":69,"is_preprint":false},{"pmid":"18058820","id":"PMC_18058820","title":"Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome.","date":"2008","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/18058820","citation_count":66,"is_preprint":false},{"pmid":"22133842","id":"PMC_22133842","title":"The PSD-95/nNOS complex: new drugs for depression?","date":"2011","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22133842","citation_count":65,"is_preprint":false},{"pmid":"9932431","id":"PMC_9932431","title":"Genetic analysis of NOS isoforms using nNOS and eNOS knockout animals.","date":"1998","source":"Progress in brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9932431","citation_count":62,"is_preprint":false},{"pmid":"19162106","id":"PMC_19162106","title":"Inhibition of nNOS reduces ischemic cell death through down-regulating calpain and caspase-3 after experimental stroke.","date":"2008","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/19162106","citation_count":60,"is_preprint":false},{"pmid":"14660484","id":"PMC_14660484","title":"Roles of iNOS and nNOS in sepsis-induced pulmonary apoptosis.","date":"2003","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14660484","citation_count":58,"is_preprint":false},{"pmid":"22989585","id":"PMC_22989585","title":"Decreased NOS1 expression in the anterior cingulate cortex in depression.","date":"2012","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/22989585","citation_count":56,"is_preprint":false},{"pmid":"14643384","id":"PMC_14643384","title":"NMDA receptor regulation of nNOS phosphorylation and induction of neuron death.","date":"2003","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/14643384","citation_count":55,"is_preprint":false},{"pmid":"15965654","id":"PMC_15965654","title":"Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder.","date":"2005","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/15965654","citation_count":52,"is_preprint":false},{"pmid":"25217629","id":"PMC_25217629","title":"The role of nNOS and PGC-1α in skeletal muscle cells.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25217629","citation_count":51,"is_preprint":false},{"pmid":"25221472","id":"PMC_25221472","title":"Mechanisms of NOS1AP action on NMDA receptor-nNOS signaling.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25221472","citation_count":51,"is_preprint":false},{"pmid":"16807372","id":"PMC_16807372","title":"Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16807372","citation_count":51,"is_preprint":false},{"pmid":"31805977","id":"PMC_31805977","title":"NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31805977","citation_count":49,"is_preprint":false},{"pmid":"9330792","id":"PMC_9330792","title":"nNOS and Ca2+ influx in rat pancreatic acinar and submandibular salivary gland cells.","date":"1997","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/9330792","citation_count":49,"is_preprint":false},{"pmid":"28577305","id":"PMC_28577305","title":"Phenotyping of nNOS neurons in the postnatal and adult female mouse hypothalamus.","date":"2017","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28577305","citation_count":46,"is_preprint":false},{"pmid":"28510048","id":"PMC_28510048","title":"nNOS regulation of skeletal muscle fatigue and exercise performance.","date":"2011","source":"Biophysical reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28510048","citation_count":44,"is_preprint":false},{"pmid":"19805695","id":"PMC_19805695","title":"Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects.","date":"2009","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19805695","citation_count":44,"is_preprint":false},{"pmid":"24691438","id":"PMC_24691438","title":"Melanoma NOS1 expression promotes dysfunctional IFN signaling.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24691438","citation_count":42,"is_preprint":false},{"pmid":"28465168","id":"PMC_28465168","title":"Nitric oxide pathway genes (NOS1AP and NOS1) are involved in PTSD severity, depression, anxiety, stress and resilience.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28465168","citation_count":42,"is_preprint":false},{"pmid":"22198001","id":"PMC_22198001","title":"Distinct regulation of nNOS and iNOS by CB2 receptor in remote delayed neurodegeneration.","date":"2011","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22198001","citation_count":40,"is_preprint":false},{"pmid":"28243469","id":"PMC_28243469","title":"NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells.","date":"2017","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/28243469","citation_count":39,"is_preprint":false},{"pmid":"10641565","id":"PMC_10641565","title":"Neuronal NO synthase (NOS1) is a major candidate gene for asthma.","date":"1999","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10641565","citation_count":39,"is_preprint":false},{"pmid":"37074530","id":"PMC_37074530","title":"nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story.","date":"2023","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/37074530","citation_count":38,"is_preprint":false},{"pmid":"31989159","id":"PMC_31989159","title":"Disrupting nNOS-PSD95 Interaction Improves Neurological and Cognitive Recoveries after Traumatic Brain Injury.","date":"2020","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/31989159","citation_count":38,"is_preprint":false},{"pmid":"11249862","id":"PMC_11249862","title":"Upregulation of juxtaglomerular NOS1 and COX-2 precedes glomerulosclerosis in fawn-hooded hypertensive rats.","date":"2001","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11249862","citation_count":38,"is_preprint":false},{"pmid":"22798524","id":"PMC_22798524","title":"Cardiomyocyte GTP cyclohydrolase 1 and tetrahydrobiopterin increase NOS1 activity and accelerate myocardial relaxation.","date":"2012","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/22798524","citation_count":37,"is_preprint":false},{"pmid":"29577585","id":"PMC_29577585","title":"nNOS-CAPON interaction mediates amyloid-β-induced neurotoxicity, especially in the early stages.","date":"2018","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/29577585","citation_count":35,"is_preprint":false},{"pmid":"30143658","id":"PMC_30143658","title":"PSD-95-nNOS Coupling Regulates Contextual Fear Extinction in the Dorsal CA3.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30143658","citation_count":34,"is_preprint":false},{"pmid":"30066461","id":"PMC_30066461","title":"Sarcolemmal loss of active nNOS (Nos1) is an oxidative stress-dependent, early event driving disuse atrophy.","date":"2018","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30066461","citation_count":34,"is_preprint":false},{"pmid":"35664081","id":"PMC_35664081","title":"Requirement of hippocampal DG nNOS-CAPON dissociation for the anxiolytic and antidepressant effects of fluoxetine.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35664081","citation_count":34,"is_preprint":false},{"pmid":"28013342","id":"PMC_28013342","title":"The TLR4-NOS1-AP1 signaling axis regulates macrophage polarization.","date":"2016","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/28013342","citation_count":33,"is_preprint":false},{"pmid":"20605417","id":"PMC_20605417","title":"A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain.","date":"2010","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/20605417","citation_count":33,"is_preprint":false},{"pmid":"26174015","id":"PMC_26174015","title":"Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy.","date":"2015","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26174015","citation_count":32,"is_preprint":false},{"pmid":"15972590","id":"PMC_15972590","title":"Suppression of stress-induced nNOS expression in the rat hypothalamus by biting.","date":"2005","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/15972590","citation_count":32,"is_preprint":false},{"pmid":"35821897","id":"PMC_35821897","title":"The expanding roles of neuronal nitric oxide synthase (NOS1).","date":"2022","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/35821897","citation_count":31,"is_preprint":false},{"pmid":"36197968","id":"PMC_36197968","title":"NOS1 mutations cause hypogonadotropic hypogonadism with sensory and cognitive deficits that can be reversed in infantile mice.","date":"2022","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36197968","citation_count":31,"is_preprint":false},{"pmid":"32779043","id":"PMC_32779043","title":"Berberine attenuates Aβ-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer's disease.","date":"2020","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32779043","citation_count":31,"is_preprint":false},{"pmid":"31609204","id":"PMC_31609204","title":"Novel long-range inhibitory nNOS-expressing hippocampal cells.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31609204","citation_count":28,"is_preprint":false},{"pmid":"18544180","id":"PMC_18544180","title":"Evidence for association between the 5' flank of the NOS1 gene and schizophrenia in the Chinese population.","date":"2008","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18544180","citation_count":28,"is_preprint":false},{"pmid":"26111153","id":"PMC_26111153","title":"Polybacterial Periodontal Pathogens Alter Vascular and Gut BH4/nNOS/NRF2-Phase II Enzyme Expression.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26111153","citation_count":27,"is_preprint":false},{"pmid":"25490993","id":"PMC_25490993","title":"Evidence for the contribution of NOS1 gene polymorphism (rs3782206) to prefrontal function in schizophrenia patients and healthy controls.","date":"2014","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25490993","citation_count":27,"is_preprint":false},{"pmid":"11408389","id":"PMC_11408389","title":"Expression and distribution of NOS1 and NOS3 in the myocardium of angiotensin II-infused rats.","date":"2001","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11408389","citation_count":26,"is_preprint":false},{"pmid":"16631350","id":"PMC_16631350","title":"Inhibition of nNOS and COX-2 expression by lutein in acute retinal ischemia.","date":"2006","source":"Nutrition (Burbank, Los Angeles County, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/16631350","citation_count":26,"is_preprint":false},{"pmid":"30193808","id":"PMC_30193808","title":"Disrupting interaction of PSD-95 with nNOS attenuates hemorrhage-induced thalamic pain.","date":"2018","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30193808","citation_count":26,"is_preprint":false},{"pmid":"17198882","id":"PMC_17198882","title":"Increased longevity of hematopoiesis in continuous bone marrow cultures derived from NOS1 (nNOS, mtNOS) homozygous recombinant negative mice correlates with radioresistance of hematopoietic and marrow stromal cells.","date":"2007","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17198882","citation_count":26,"is_preprint":false},{"pmid":"29319606","id":"PMC_29319606","title":"Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice.","date":"2018","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/29319606","citation_count":25,"is_preprint":false},{"pmid":"32061134","id":"PMC_32061134","title":"NOS1AP polymorphisms reduce NOS1 activity and interact with prolonged repolarization in arrhythmogenesis.","date":"2021","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/32061134","citation_count":25,"is_preprint":false},{"pmid":"32193098","id":"PMC_32193098","title":"Macrophage neuronal nitric oxide synthase (NOS1) controls the inflammatory response and foam cell formation in atherosclerosis.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32193098","citation_count":25,"is_preprint":false},{"pmid":"31328777","id":"PMC_31328777","title":"Somatostatin+/nNOS+ neurons are involved in delta electroencephalogram activity and cortical-dependent recognition memory.","date":"2019","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/31328777","citation_count":25,"is_preprint":false},{"pmid":"30352768","id":"PMC_30352768","title":"Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality?","date":"2018","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/30352768","citation_count":25,"is_preprint":false},{"pmid":"22309983","id":"PMC_22309983","title":"Amitriptyline attenuates astrocyte activation and morphine tolerance in rats: role of the PSD-95/NR1/nNOS/PKCγ signaling pathway.","date":"2012","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22309983","citation_count":25,"is_preprint":false},{"pmid":"28235709","id":"PMC_28235709","title":"Role of ERK1/2 activation and nNOS uncoupling on endothelial dysfunction induced by lysophosphatidylcholine.","date":"2016","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/28235709","citation_count":24,"is_preprint":false},{"pmid":"33099751","id":"PMC_33099751","title":"Leptin Contributes to Neuropathic Pain via Extrasynaptic NMDAR-nNOS Activation.","date":"2020","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33099751","citation_count":24,"is_preprint":false},{"pmid":"15893765","id":"PMC_15893765","title":"Targeted nNOS gene transfer into the cardiac vagus rapidly increases parasympathetic function in the pig.","date":"2005","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15893765","citation_count":24,"is_preprint":false},{"pmid":"32218855","id":"PMC_32218855","title":"NOS1 expression promotes proliferation and invasion and enhances chemoresistance in ovarian cancer.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32218855","citation_count":23,"is_preprint":false},{"pmid":"24622112","id":"PMC_24622112","title":"NOS1 methylation and carotid artery intima-media thickness in children.","date":"2014","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24622112","citation_count":23,"is_preprint":false},{"pmid":"17892518","id":"PMC_17892518","title":"Endothelin(A) (ET(A)) and ET(B) receptor-mediated regulation of nitric oxide synthase 1 (NOS1) and NOS3 isoforms in the renal inner medulla.","date":"2007","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17892518","citation_count":23,"is_preprint":false},{"pmid":"15542708","id":"PMC_15542708","title":"Differential response of nNOS knockout mice to MDMA (\"ecstasy\")- and methamphetamine-induced psychomotor sensitization and neurotoxicity.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15542708","citation_count":23,"is_preprint":false},{"pmid":"32579471","id":"PMC_32579471","title":"An autophagic deficit in the uterine vessel microenvironment provokes hyperpermeability through deregulated VEGFA, NOS1, and CTNNB1.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32579471","citation_count":22,"is_preprint":false},{"pmid":"32353527","id":"PMC_32353527","title":"Effects of selective inhibition of nNOS and iNOS on neuropathic pain in rats.","date":"2020","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32353527","citation_count":22,"is_preprint":false},{"pmid":"31153640","id":"PMC_31153640","title":"Mitochondrial NOS1 suppresses apoptosis in colon cancer cells through increasing SIRT3 activity.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31153640","citation_count":21,"is_preprint":false},{"pmid":"33494625","id":"PMC_33494625","title":"BH4 Increases nNOS Activity and Preserves Left Ventricular Function in Diabetes.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/33494625","citation_count":21,"is_preprint":false},{"pmid":"25300364","id":"PMC_25300364","title":"Neuronal nitric oxide synthase (nNOS, NOS1) rs693534 and rs7977109 variants and risk for restless legs syndrome.","date":"2014","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/25300364","citation_count":21,"is_preprint":false},{"pmid":"24710314","id":"PMC_24710314","title":"Hippocampal nNOS inhibition induces an antidepressant-like effect: involvement of 5HT1A receptors.","date":"2014","source":"Behavioural pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24710314","citation_count":21,"is_preprint":false},{"pmid":"33402546","id":"PMC_33402546","title":"nNOS-mediated protein-protein interactions: promising targets for treating neurological and neuropsychiatric disorders.","date":"2020","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/33402546","citation_count":20,"is_preprint":false},{"pmid":"35105915","id":"PMC_35105915","title":"Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35105915","citation_count":20,"is_preprint":false},{"pmid":"20016223","id":"PMC_20016223","title":"Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.","date":"2009","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20016223","citation_count":20,"is_preprint":false},{"pmid":"29605772","id":"PMC_29605772","title":"NOS1 mediates AP1 nuclear translocation and inflammatory response.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29605772","citation_count":19,"is_preprint":false},{"pmid":"30675218","id":"PMC_30675218","title":"NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30675218","citation_count":19,"is_preprint":false},{"pmid":"21620982","id":"PMC_21620982","title":"NOS1 ex1f-VNTR polymorphism influences prefrontal brain oxygenation during a working memory task.","date":"2011","source":"NeuroImage","url":"https://pubmed.ncbi.nlm.nih.gov/21620982","citation_count":19,"is_preprint":false},{"pmid":"36682419","id":"PMC_36682419","title":"nNOS-induced tyrosine nitration of TRKB impairs BDNF signaling and restrains neuronal plasticity.","date":"2023","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36682419","citation_count":18,"is_preprint":false},{"pmid":"18095156","id":"PMC_18095156","title":"Spatiotemporal expression of PSD-95 and nNOS after rat sciatic nerve injury.","date":"2007","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/18095156","citation_count":18,"is_preprint":false},{"pmid":"29782905","id":"PMC_29782905","title":"Pathology of nNOS-Expressing GABAergic Neurons in Mouse Model of Alzheimer's Disease.","date":"2018","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29782905","citation_count":18,"is_preprint":false},{"pmid":"28126743","id":"PMC_28126743","title":"Superoxide generation from nNOS splice variants and its potential involvement in redox signal regulation.","date":"2017","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/28126743","citation_count":18,"is_preprint":false},{"pmid":"27041589","id":"PMC_27041589","title":"Human Ischemic Cardiomyopathy Shows Cardiac Nos1 Translocation and its Increased Levels are Related to Left Ventricular Performance.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27041589","citation_count":18,"is_preprint":false},{"pmid":"19513863","id":"PMC_19513863","title":"No association between polymorphisms of neuronal oxide synthase 1 gene (NOS1) and schizophrenia in a Japanese population.","date":"2009","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19513863","citation_count":17,"is_preprint":false},{"pmid":"33501735","id":"PMC_33501735","title":"NOS1-mediated macrophage and endothelial cell interaction in the progression of atherosclerosis.","date":"2021","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/33501735","citation_count":16,"is_preprint":false},{"pmid":"32283261","id":"PMC_32283261","title":"Changes of nNOS expression in the tuberal hypothalamic nuclei during ageing.","date":"2020","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32283261","citation_count":16,"is_preprint":false},{"pmid":"29703249","id":"PMC_29703249","title":"miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context.","date":"2018","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/29703249","citation_count":16,"is_preprint":false},{"pmid":"31266455","id":"PMC_31266455","title":"Dystrophin R16/17 protein therapy restores sarcolemmal nNOS in trans and improves muscle perfusion and function.","date":"2019","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/31266455","citation_count":16,"is_preprint":false},{"pmid":"26086921","id":"PMC_26086921","title":"On the role of NOS1 ex1f-VNTR in ADHD-allelic, subgroup, and meta-analysis.","date":"2015","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26086921","citation_count":16,"is_preprint":false},{"pmid":"23826716","id":"PMC_23826716","title":"Association analysis of nitric oxide synthases: NOS1, NOS2A and NOS3 genes, with multiple sclerosis.","date":"2013","source":"Annals of human biology","url":"https://pubmed.ncbi.nlm.nih.gov/23826716","citation_count":16,"is_preprint":false},{"pmid":"24161722","id":"PMC_24161722","title":"Development of nNOS-positive neurons in the rat sensory and sympathetic ganglia.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24161722","citation_count":16,"is_preprint":false},{"pmid":"25672665","id":"PMC_25672665","title":"The neuronal nitric oxide synthase (nNOS) gene and neuroprotection against alcohol toxicity.","date":"2015","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25672665","citation_count":15,"is_preprint":false},{"pmid":"31043586","id":"PMC_31043586","title":"nNOS/GSNOR interaction contributes to skeletal muscle differentiation and homeostasis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31043586","citation_count":15,"is_preprint":false},{"pmid":"26283425","id":"PMC_26283425","title":"Neuronal Nitric Oxide Synthase (nNOS, NOS1) rs693534 and rs7977109 Variants and Risk for Migraine.","date":"2015","source":"Headache","url":"https://pubmed.ncbi.nlm.nih.gov/26283425","citation_count":15,"is_preprint":false},{"pmid":"27254746","id":"PMC_27254746","title":"Activity and MeCP2-dependent regulation of nNOS levels in enteric neurons.","date":"2016","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/27254746","citation_count":15,"is_preprint":false},{"pmid":"37080493","id":"PMC_37080493","title":"Nos1+ and Nos1- excitatory neurons in the BLA regulate anxiety- and depression-related behaviors oppositely.","date":"2023","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/37080493","citation_count":14,"is_preprint":false},{"pmid":"33771575","id":"PMC_33771575","title":"nNOS induction and NOSIP interaction impact granulopoiesis and neutrophil differentiation by modulating nitric oxide generation.","date":"2021","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33771575","citation_count":14,"is_preprint":false},{"pmid":"36470319","id":"PMC_36470319","title":"Male minipuberty involves the gonad-independent activation of preoptic nNOS neurons.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36470319","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54541,"output_tokens":9312,"usd":0.151651,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19742,"output_tokens":6092,"usd":0.125505,"stage2_stop_reason":"end_turn"},"total_usd":0.277156,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"MnSOD is enriched in nNOS neurons and is required for their resistance to NMDA-mediated neurotoxicity; antisense knockdown of MnSOD renders nNOS neurons susceptible to NMDA toxicity, and adenoviral MnSOD transfer restores resistance in MnSOD-/- cultures.\",\n      \"method\": \"Antisense knockdown, adenoviral gene transfer, cortical neuron cultures, MnSOD-/- mice\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (antisense, adenoviral OE, KO mice) replicated across cell lines and primary cultures in one study\",\n      \"pmids\": [\"9482791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FMRP activates translation of NOS1 in the developing human neocortex by interacting with coding-region binding motifs on human NOS1 mRNA (absent from mouse Nos1 mRNA); NOS1 protein is severely reduced in developing human FXS brain but not in FMRP-deficient mice.\",\n      \"method\": \"Co-immunoprecipitation, polyribosome fractionation, postmortem human tissue, FMRP-KO mouse tissue\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, species-comparative biochemistry, human postmortem validation, single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"22579290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Excitotoxic stimulation recruits NOS1AP to nNOS in cortical neurons; NOS1AP interacts with p38MAPK-activating kinase MKK3, and competing with the nNOS–NOS1AP PDZ interaction reduces p38MAPK activation and subsequent neuronal death. A cell-permeable competing peptide doubled surviving tissue in a neonatal rat hypoxia-ischemia model.\",\n      \"method\": \"Co-IP, siRNA knockdown, cell-permeable competing peptide, rat cortical neuron culture, in vivo neonatal HI model\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, siRNA KD, peptide competition in vitro and in vivo, multiple orthogonal methods in one study\",\n      \"pmids\": [\"23658158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NOS1 S-nitrosylates HDAC2 at Cys262/Cys274, reducing HDAC2 binding to STAT1, impairing HDAC2 recruitment to ISG promoters, decreasing H4K16 deacetylation, and suppressing interferon-stimulated gene expression to promote melanoma immune escape and lung metastasis.\",\n      \"method\": \"Biotin-switch S-nitrosylation assay, Co-IP, ChIP-qPCR, luciferase reporter, HDAC2-C262A/C274A site mutant, xenograft mouse model, flow cytometry\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct S-nitrosylation assay, site-directed mutagenesis abolishing effect, ChIP validation, in vivo confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"31805977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NMDA receptor activation decreases nNOS phosphorylation via calcineurin- and PP1/PP2A-dependent dephosphorylation, increasing nNOS enzymatic activity (measured by nitrotyrosine accumulation) and driving neuron death in a cell-autonomous pathway.\",\n      \"method\": \"Quantitative digital microscopy, NMDA receptor antagonists, calcineurin/phosphatase inhibitors, nitrotyrosine immunostaining, TUNEL assay in rat cortical neurons\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with multiple inhibitors and two independent readouts (nitrotyrosine, TUNEL); single lab\",\n      \"pmids\": [\"14643384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Augmenting nNOS–CAPON interaction in mouse hippocampus causes anxiogenic behavior; disrupting it produces anxiolytic effects. The anxiogenic mechanism involves Dexras1 S-nitrosylation and downstream ERK signaling. Small-molecule blockers of nNOS–CAPON binding recapitulate the anxiolytic effect.\",\n      \"method\": \"Viral overexpression, competing peptides (Tat-CAPON-12C), small-molecule binding blockers, behavioral assays (chronic mild stress model), co-IP, western blot\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic OE/disruption, peptide competition, small-molecule validation, in vivo behavioral and molecular readouts, multiple orthogonal approaches\",\n      \"pmids\": [\"25129479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"nNOS-induced nitration of tyrosine 816 on TRKB inhibits TRKB phosphorylation and PLCγ1 binding, triggers clathrin-dependent TRKB endocytosis via AP-2, and promotes lysosomal TRKB degradation, constituting a molecular brake on neuronal plasticity. Chronic nNOS inhibition in vivo reduced TRKB nitration and promoted ocular dominance plasticity.\",\n      \"method\": \"In vitro nitration assays, site-specific mutagenesis (Y816), co-IP, endocytosis assays, nNOS inhibitor in vivo, monocular deprivation plasticity paradigm\",\n      \"journal\": \"Progress in neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct post-translational modification demonstrated, site-specific mutagenesis, functional in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"36682419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NOS1 S-nitrosylates PTEN, activating the AKT/mTOR pathway to inhibit excessive autophagy and promote survival of nasopharyngeal carcinoma cells; Hsp90 inhibitor geldanamycin blocks NOS1 mitochondrial translocation and reverses apoptosis resistance.\",\n      \"method\": \"Biotin-switch S-nitrosylation assay, NOS1 siRNA/pharmacological inhibition, autophagy inhibitor rescue, in vivo xenograft, western blot\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct S-nitrosylation assay, KD/KO + rescue, in vivo validation; single lab\",\n      \"pmids\": [\"28243469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Sarcolemmal nNOS expression is dramatically reduced in sarcoglycan-deficient muscular dystrophy (alpha-, beta-, delta-, gamma-sarcoglycan mutations) even when dystrophin and syntrophin are present, demonstrating that the intact sarcoglycan-sarcospan complex is required to maintain nNOS at the sarcolemma.\",\n      \"method\": \"Western blot, immunofluorescence in animal models and patient biopsy tissue\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein localization by fractionation and immunostaining in multiple animal models and human tissue; single lab, two orthogonal methods\",\n      \"pmids\": [\"12409321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Biglycan, an extracellular matrix molecule, regulates sarcolemmal localization of nNOS, dystrobrevin, and syntrophin; purified biglycan induces nNOS redistribution to the plasma membrane in cultured muscle cells, and biglycan protein injection into biglycan-null muscle restores sarcolemmal nNOS.\",\n      \"method\": \"Biglycan-null mouse analysis, purified biglycan addition to cultured muscle cells, intramuscular biglycan protein injection, immunofluorescence\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (KO) and gain-of-function (protein injection) with localization readout; single lab\",\n      \"pmids\": [\"16807372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cardiac-myocyte GTP cyclohydrolase 1 (GCH1) overexpression increases intracellular BH4 and constitutively increases NOS1 activity; NOS1 inhibition abolishes GCH1-dependent differences in ICaL density, PLB Ser16 phosphorylation, Ca2+ decay rate, and myocardial relaxation, placing NOS1 as the downstream mediator of BH4-dependent cardiac relaxation.\",\n      \"method\": \"Transgenic mouse model, NOS1 inhibition (SMTC), isolated hearts, field-stimulated cardiomyocytes, Ca2+ imaging, patch clamp\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic OE + pharmacological inhibition with multiple orthogonal functional readouts (Ca2+ handling, ICaL, PLB phosphorylation, contractility) in one rigorous study\",\n      \"pmids\": [\"22798524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BH4-mediated nNOS activity in cardiomyocytes drives insulin-independent glucose uptake via NO/sGC/PKG-dependent increase in GLUT-1 plasmalemmal density; CRISPR/Cas9 knockout of nNOS in mGCH1-Tg mice abolishes BH4-dependent protection of LV function in diabetes.\",\n      \"method\": \"CRISPR/Cas9 nNOS KO, transgenic GCH1 overexpression, echocardiography, glucose uptake assay, HEK cell S-nitrosoglutathione treatment, 31P-MRS\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO abolishes phenotype, multiple mechanistic and functional readouts, confirmatory cell-based experiments; single rigorous study\",\n      \"pmids\": [\"33494625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SGLT1 at the macula densa senses luminal glucose, upregulating NOS1 expression and Ser1417 phosphorylation; macula densa-specific NOS1 knockout abolishes glucose-stimulated NO production, blunting of TGF response, and GFR elevation, establishing a SGLT1-NOS1 axis in hyperglycemia-induced glomerular hyperfiltration.\",\n      \"method\": \"Macula densa-specific NOS1 knockout mice (AQP2-Cre × NOS1-flox), microperfusion, micropuncture, FITC-inulin GFR, SGLT1 inhibitor, western blot\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with multiple functional readouts (NO, TGF, GFR), pharmacological validation, mechanistic confirmation of phosphorylation\",\n      \"pmids\": [\"30867247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Collecting duct (CD)-specific deletion of NOS1 causes impaired natriuresis/diuresis and salt-sensitive hypertension under high-sodium diet, demonstrating that CD NOS1 is required for fluid-electrolyte homeostasis.\",\n      \"method\": \"AQP2-Cre × NOS1-flox conditional KO mice, dietary sodium challenge, urine electrolyte/NOx measurement, telemetric blood pressure\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with multiple functional readouts; single lab, rigorous in vivo approach\",\n      \"pmids\": [\"23608660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"nNOS interneurons in the nucleus accumbens core (~1% of neurons) receive mGluR5-activated glutamate spillover, produce NO, and drive matrix metalloproteinase (MMP-2/9) activation and transient synaptic potentiation (AMPA current increase) in MSNs, thereby mediating cue-induced cocaine relapse.\",\n      \"method\": \"NO-sensitive electrodes, chemogenetic (DREADD) activation/silencing of nNOS interneurons, transgenic caspase ablation, MMP assay, whole-cell electrophysiology, rodent self-administration/reinstatement model\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific chemogenetics, selective ablation, electrophysiology, electrochemistry; multiple orthogonal methods in one study\",\n      \"pmids\": [\"28123012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Contextual fear extinction induces a shift from PSD-95–nNOS to PSD-95–TrkB association in dorsal hippocampus (CA3); disrupting PSD-95–nNOS coupling in dorsal CA3 upregulates ERK phosphorylation and BDNF, promotes BDNF–TrkB–PSD-95 association, and enhances fear extinction.\",\n      \"method\": \"Co-immunoprecipitation, western blot, stereotaxic nNOS–PSD-95 disruptor peptide injection, behavioral fear conditioning/extinction paradigm\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing complex shift, peptide disruption with defined molecular and behavioral readouts; single lab\",\n      \"pmids\": [\"30143658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Disrupting the nNOS–PSD-95 interaction with ZL006 inhibits nNOS-PSD95 binding, reduces p38 MAPK activation and apoptotic marker expression (active caspase-3, PARP-1), and improves neurological, sensorimotor, and cognitive outcomes after traumatic brain injury in mice.\",\n      \"method\": \"Co-IP, cortical neuronal cultures (glutamate excitotoxicity), mouse CCI model, TUNEL/phospho-p38 immunostaining, western blot, behavioral tests\",\n      \"journal\": \"Cerebral cortex\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirmation of target engagement, pharmacological disruption with multiple mechanistic and functional readouts; single lab\",\n      \"pmids\": [\"31989159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"nNOS–NOS1AP interaction is required for excitotoxic p38 MAPK signaling and neuropathic pain; a peptide inhibitor (TAT-GESV) disrupts nNOS–NOS1AP binding (but not nNOS–PSD95), blocks glutamate/glycine-induced neurotoxicity in cortical neurons, and suppresses paclitaxel- and nerve-injury-induced allodynia via blockade of p53-Ser15 phosphorylation downstream of p38 MAPK.\",\n      \"method\": \"In vitro binding assay, cortical neuron excitotoxicity, intrathecal peptide delivery, behavioral allodynia testing, western blot (phospho-p53)\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding disruption confirmed, in vivo functional validation with mechanistic readout; single lab\",\n      \"pmids\": [\"29319606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Disrupting PSD-95–nNOS interaction with ZL006 blocks hemorrhage-induced increase in PSD-95–nNOS binding and membrane translocation of nNOS in thalamic neurons, alleviating thalamic pain hypersensitivity when given before (but not after) hemorrhage.\",\n      \"method\": \"Co-IP, western blot, stereotaxic collagenase thalamic hemorrhage model, ZL006 systemic treatment, behavioral pain testing\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirmation, pharmacological disruption with molecular (membrane translocation) and behavioral readouts; single lab\",\n      \"pmids\": [\"30193808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"nNOS–CAPON interaction is increased by Aβ treatment in vitro and in APP/PS1 mouse hippocampus; blocking nNOS–CAPON interaction rescues memory and dendritic impairments in 4-month-old APP/PS1 mice. Downstream mechanism involves S-nitrosylation of Dexras1 and inhibition of ERK–CREB–BDNF pathway.\",\n      \"method\": \"Co-IP, APP/PS1 transgenic mice, nNOS–CAPON competing peptides, behavioral memory tests, dendritic spine morphology, western blot\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in vivo genetic/pharmacological disruption, multiple functional readouts; single lab\",\n      \"pmids\": [\"29577585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Fluoxetine prevents chronic stress-induced nNOS–CAPON upregulation and coupling in the dentate gyrus; 5-HT1AR activation (by 8-OH-DPAT or elevated 5-HT) decreases nNOS–CAPON binding, and augmenting nNOS–CAPON binding neutralizes fluoxetine/5-HT1AR-induced synaptic plasticity (spine density, BDNF, ERK/CREB/synapsin phosphorylation) and anxiolytic/antidepressant effects.\",\n      \"method\": \"Co-IP, viral overexpression/competition constructs, 5-HT1AR agonist/antagonist pharmacology, CMS and CORT mouse models, dendritic spine analysis, behavioral tests\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, pharmacological and genetic modulation with multiple molecular and behavioral readouts; single lab\",\n      \"pmids\": [\"35664081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NOS1AP SNPs (rs16847548, rs4657139) associated with arrhythmia risk reduce NOS1 expression and co-localization with NOS1AP in hiPSC-CMs from symptomatic LQT1 patients. NOS1 inhibition in guinea pig cardiomyocytes prolongs APD, enhances ICaL and INaL, slows Ca2+ decay, and induces delayed afterdepolarizations, establishing that NOS1AP SNPs cause NOS1 loss of function contributing to arrhythmogenesis.\",\n      \"method\": \"hiPSC-CMs from LQT1 patients with distinct NOS1AP genotypes, guinea pig cardiomyocyte NOS1 inhibition (SMTC, L-VNIO), action-potential clamp, patch clamp, Ca2+ fluorimetry\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — patient-derived hiPSC-CMs paired with pharmacological model, multiple electrophysiological and Ca2+ handling readouts; mechanistically rigorous single study\",\n      \"pmids\": [\"32061134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Unloading-induced redistribution of active nNOS from the sarcolemma to the sarcoplasm precedes myofiber atrophy and depends on mitochondrial-derived oxidant species; displaced nNOS activity drives FoxO3 nuclear translocation to initiate muscle atrophy. In vivo inhibition of nNOS before and during unloading prevents FoxO3 nuclear accumulation.\",\n      \"method\": \"Human bed-rest biopsies, rat unloading model, NADPH-diaphorase histochemistry, immunofluorescence, mitochondrial superoxide measurement, tropomyosin disulfide analysis, FoxO3 nuclear localization assay, in vivo nNOS inhibition\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human and rodent models, multiple orthogonal methods (histochemistry, fractionation, oxidative stress markers, nuclear localization), pharmacological validation; single rigorous study\",\n      \"pmids\": [\"30066461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Adenoviral nNOS gene transfer into the cardiac vagus increases nNOS protein expression selectively in the right vagus within 9 hours and enhances baroreflex sensitivity and heart rate responses to right vagal stimulation in pigs, demonstrating NOS1-dependent facilitation of cardiac vagal neurotransmission in vivo.\",\n      \"method\": \"Adenoviral nNOS gene transfer in vivo (pig), western blot, baroreflex/vagal stimulation electrophysiology\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain-of-function with molecular and functional readouts; single lab, large-animal model\",\n      \"pmids\": [\"15893765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"nNOS-derived NO facilitates Fos–Jun dimerization (AP-1) driving IL-12 and IL-23 expression in LPS-stimulated macrophages (TLR4-NOS1-AP1 axis); NOS1 inhibition switches AP-1 composition to ATF2–Jun, converting macrophages from IL-12high/IL-23high/IL-10low (M1) to IL-10high (M2) phenotype.\",\n      \"method\": \"Pharmacological NOS1 inhibition (TRIM), LPS-stimulated Raw 264.7 and THP1 macrophages, dimerization assays, cytokine measurement\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological loss-of-function with defined molecular mechanism (AP-1 subunit switching) and cytokine readouts; single lab\",\n      \"pmids\": [\"28013342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"nNOS is present in mitochondria of colon cancer cells; mitochondrial NOS1 suppresses mitochondrial superoxide and cisplatin-induced apoptosis by enhancing SIRT3 activity (mtNOS1-SIRT3-SOD2 axis). Hsp90 inhibitor geldanamycin blocks NOS1 mitochondrial translocation and reverses apoptosis resistance.\",\n      \"method\": \"Subcellular fractionation, stable NOS1 overexpression, geldanamycin treatment, SIRT3 activity assay, mitochondrial superoxide measurement, flow cytometry apoptosis assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation demonstrating mitochondrial localization, functional link via Hsp90 inhibition, SIRT3 activity readout; single lab\",\n      \"pmids\": [\"31153640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"nNOS splice variant nNOS-α generates ~2.3-fold more superoxide than nNOS-µ in electron-uncoupling reactions (EPR measurement) and in HEK293 cells upon calcium ionophore stimulation; nNOS-α expressing cells produce more 8-nitroguanosine-cGMP (a NO/ROS second messenger) than nNOS-µ expressing cells.\",\n      \"method\": \"Electron paramagnetic resonance (EPR), HEK293 stable transfection, calcium ionophore stimulation, immunocytochemistry for 8-nitroguanosine-cGMP\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro EPR measurement and cellular assays with two splice variants; single lab\",\n      \"pmids\": [\"28126743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NOS1 loss-of-function mutations cause congenital hypogonadotropic hypogonadism by disrupting GnRH neuron function; NOS1 is transiently expressed by GnRH neurons in the human and mouse nose, and Nos1-deficient mice show dose-dependent defects in sexual maturation, olfaction, hearing, and cognition. Inhaled NO treatment during minipuberty rescues reproductive and behavioral phenotypes in Nos1-deficient mice.\",\n      \"method\": \"Whole-exome sequencing, in vitro NOS1 mutant activity assay (nitrite/cGMP production), Nos1-KO mouse model, pharmacological NO inhibition with critical time-window experiment, inhaled NO rescue\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — human genetics with functional validation of mutants in vitro, mouse KO phenotyping, pharmacological rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"36197968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In male mice, preoptic nNOS neurons (co-expressing ERα but not AR) show a sharp increase in Ser1412 phosphorylation at postnatal day 23 (minipuberty onset) that occurs independent of gonads; pharmacological ERα blockade during the infantile period blunts nNOS Ser1412 phosphorylation, linking extragonadal estrogen signaling through ERα to nNOS activation during minipuberty.\",\n      \"method\": \"Gonadectomy, ERα-selective pharmacological blockade, immunohistochemistry for phospho-nNOS Ser1412 and ERα/AR, nNOS-deficient mice, hormonal profiling (RIA/ELISA)\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gonadectomy + pharmacological dissection with defined molecular readout; single lab\",\n      \"pmids\": [\"36470319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"nNOS and the denitrosylase GSNOR co-localize at the sarcolemma and co-immunoprecipitate in C2C12 myotubes and mouse myofibers; GSNOR expression decreases in mouse models of muscular dystrophy, aging, and ALS, suggesting that nNOS–GSNOR interaction regulates S-nitrosylation homeostasis in skeletal muscle.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, C2C12 differentiation time-course, disease model muscle tissue analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP confirmed in cells and myofibers, replicated across multiple disease models; single lab\",\n      \"pmids\": [\"31043586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"After stroke (ischemia-reperfusion), nNOS activity increases with Ser1412 phosphorylation; GSNO treatment reduces nNOS Ser1412 phosphorylation and activity by inhibiting the upstream AMPK–LKB1 axis, thereby reducing peroxynitrite levels and providing neuroprotection.\",\n      \"method\": \"Rat cerebral IR model, GSNO treatment, nNOS activity assay, phospho-nNOS western blot, AMPK activator/inhibitor pharmacology\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological epistasis linking AMPK→nNOS Ser1412 phosphorylation→peroxynitrite with multiple converging inhibitors; single lab\",\n      \"pmids\": [\"26174015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Novel long-range inhibitory nNOS-expressing hippocampal neurons (LINCs) project extrahippocampally (tenia tecta, diagonal band, retromammillary nucleus) and locally to CA1; selective optogenetic activation of LINCs strongly influences hippocampal oscillations and interregional coherence.\",\n      \"method\": \"Intersectional viral vector approach in mice, optogenetic activation, electrophysiology, anatomical tracing\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific genetic targeting with optogenetic functional readout; single lab\",\n      \"pmids\": [\"31609204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SST+/nNOS+ cortical neuron-specific nNOS knockout mice show impaired homeostatic slow-wave (delta) activity after sleep loss and deficits in cortex-dependent recognition memory, placing NOS1 in SST interneurons as required for SWA homeostasis and cortical memory processes.\",\n      \"method\": \"Cell-type-specific Cre-mediated nNOS KO (SST-Cre × NOS1-flox), EEG/sleep recording, recognition memory behavioral testing\",\n      \"journal\": \"Sleep\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with EEG and behavioral readouts; single lab\",\n      \"pmids\": [\"31328777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"nNOS-derived NO promotes OxLDL uptake and proinflammatory cytokine expression by macrophages; NOS1 inhibition (L-NAME) suppresses OxLDL uptake and cytokine release, implicating NOS1 in foam cell formation and atherosclerosis progression.\",\n      \"method\": \"Pharmacological NOS1 inhibition, OxLDL uptake assay, cytokine ELISA, macrophage culture\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single pharmacological inhibitor approach, single lab, no genetic validation\",\n      \"pmids\": [\"33501735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"nNOS (localized at the plasma membrane of pancreatic acinar and submandibular salivary gland cells) mediates agonist-activated Ca2+ influx through generation of cGMP; nNOS inhibitor 7-NI selectively blocked bombesin-evoked but not CCK-JMV-180-evoked Ca2+ oscillations and Ca2+ influx.\",\n      \"method\": \"Pharmacological NOS inhibition (7-NI, NOS pathway inhibitors), cGMP assay, [Ca2+]i fluorimetry, western blot and immunolocalization of NOS isoforms\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with isoform-selective inhibitor, immunolocalization to distinguish NOS isoforms, multiple readouts; single lab\",\n      \"pmids\": [\"9330792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"nNOS-derived NO promotes C/EBPα-dependent neutrophil differentiation through the G-CSFR–STAT3 axis; in vivo nNOS inhibition abrogates granulopoiesis (decreased BM mature and progenitor neutrophils). NOSIP (NOS inhibitory protein) expression decreases during the final stage of differentiation, correlating with augmented NO release and differentiation completion.\",\n      \"method\": \"nNOS overexpression in K562 cells, nNOS inhibitor in vivo (mice) and in vitro (human CD34+ HSPCs), surface marker/transcription factor analysis, NOSIP expression profiling, CML patient neutrophils vs healthy controls\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in multiple systems (cell line, mouse, human primary cells) with defined molecular pathway readouts; single lab\",\n      \"pmids\": [\"33771575\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOS1 (nNOS) is a Ca2+/calmodulin-activated enzyme that produces nitric oxide (NO) and, via splice-variant-dependent electron uncoupling, superoxide; its activity and subcellular localization are controlled by dephosphorylation (calcineurin/PP1/PP2A at inhibitory sites) and phosphorylation (AMPK→Ser1412 activating site), as well as by scaffolding interactions through its PDZ domain with PSD-95 (coupling it to NMDAR-mediated excitotoxic p38 MAPK–NOS1AP signaling), CAPON/Dexras1-ERK (modulating anxiety, depression, and addiction), and SERT; sarcolemmal targeting requires the intact dystrophin–sarcoglycan–syntrophin complex and biglycan; NO produced by NOS1 exerts downstream effects through S-nitrosylation of targets including HDAC2, PTEN, and TRKB (tyrosine nitration), through NO/sGC/PKG/GLUT-1-dependent cardiac glucose uptake, through MMP activation in accumbens circuits, and through cGMP-dependent Ca2+ influx regulation, collectively placing NOS1 at a nexus of neuronal excitotoxicity, synaptic plasticity, cardiac relaxation, renal sodium handling, muscle homeostasis, granulopoiesis, and reproductive neuroendocrine control.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NOS1 (nNOS) is a Ca2+/calmodulin-regulated nitric oxide synthase whose activity, subcellular targeting, and downstream signaling place it at a hub spanning neuronal excitotoxicity, synaptic plasticity, cardiac and renal physiology, muscle homeostasis, and neuroendocrine control [#14, #27]. Its catalytic output is gated by phosphorylation and cofactor supply: activating Ser1412/Ser1417 phosphorylation downstream of an AMPK\\u2013LKB1 axis and of SGLT1- and ER\\u03b1-driven inputs drives NO production [#12, #28, #30], while NMDA-receptor-triggered calcineurin/PP1/PP2A dephosphorylation paradoxically raises nitrotyrosine-generating activity to promote neuronal death [#4]; tetrahydrobiopterin (BH4) availability set by GCH1 constitutively tunes activity in cardiomyocytes [#10], and splice variant identity (nNOS-\\u03b1 vs -\\u00b5) determines the balance between NO and uncoupled superoxide output [#26]. NOS1 signals through scaffold-organized protein complexes: PDZ-domain coupling to PSD-95 links it to NMDAR-driven, NOS1AP\\u2013MKK3\\u2013p38 MAPK excitotoxic and pain signaling [#2, #17], while its interaction with CAPON drives Dexras1 S-nitrosylation and ERK\\u2013CREB\\u2013BDNF modulation underlying anxiety, depression, and amyloid-associated memory deficits [#5, #19, #20]. NO and reactive nitrogen species produced by NOS1 act on specific targets through S-nitrosylation of HDAC2 (suppressing interferon-stimulated genes for melanoma immune escape) and PTEN (activating AKT/mTOR), through tyrosine nitration of TRKB (a brake on plasticity), and through cGMP-dependent control of Ca2+ influx and GLUT-1-mediated cardiac glucose uptake [#3, #6, #7, #11, #34]. At the sarcolemma, NOS1 localization requires the intact sarcoglycan complex and the matrix proteoglycan biglycan, and its mislocalization to the sarcoplasm drives FoxO3-dependent muscle atrophy [#8, #9, #22]. NOS1 loss-of-function mutations cause congenital hypogonadotropic hypogonadism by impairing GnRH neuron function, a phenotype rescuable by inhaled NO during minipuberty [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that nNOS-expressing neurons are paradoxically protected from their own NO output, identifying MnSOD as the antioxidant shield that confers excitotoxic resistance.\",\n      \"evidence\": \"Antisense knockdown and adenoviral MnSOD transfer in cortical neuron cultures and MnSOD-/- mice\",\n      \"pmids\": [\"9482791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define the molecular link between NO/superoxide flux and cell death in unprotected neurons\", \"Does not address how MnSOD expression is restricted to nNOS neurons\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved how NMDA receptor activation upregulates NOS1 enzymatic activity, showing calcineurin- and PP1/PP2A-dependent dephosphorylation increases nitrotyrosine accumulation and drives cell-autonomous death.\",\n      \"evidence\": \"Pharmacological phosphatase/calcineurin inhibition with nitrotyrosine and TUNEL readouts in rat cortical neurons\",\n      \"pmids\": [\"14643384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific dephosphorylated residue(s) not mapped\", \"Single-lab pharmacological dissection without genetic confirmation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the NOS1AP\\u2013MKK3\\u2013p38 MAPK axis as the excitotoxic effector downstream of nNOS, and demonstrated a druggable PDZ interaction by neuroprotective peptide competition in vivo.\",\n      \"evidence\": \"Reciprocal Co-IP, siRNA, cell-permeable competing peptide in cortical neurons and a neonatal rat hypoxia-ischemia model\",\n      \"pmids\": [\"23658158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish stoichiometry of the nNOS\\u2013NOS1AP\\u2013MKK3 complex\", \"Long-term outcomes of peptide intervention not assessed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that the nNOS\\u2013CAPON scaffold interaction bidirectionally controls affective behavior via Dexras1 S-nitrosylation and ERK signaling, validating it as an anxiolytic/antidepressant target.\",\n      \"evidence\": \"Viral overexpression/disruption, competing peptides, small-molecule blockers, and behavioral assays in mice\",\n      \"pmids\": [\"25129479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Brain-region specificity of the behavioral effect not fully delineated\", \"Direct S-nitrosylation site on Dexras1 within this paradigm not mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed NOS1 downstream of GCH1/BH4 as the mediator of cardiac relaxation, linking cofactor supply to Ca2+ handling and contractility.\",\n      \"evidence\": \"Transgenic GCH1 overexpression with NOS1 inhibition, Ca2+ imaging, patch clamp, and contractility measurement in isolated hearts and myocytes\",\n      \"pmids\": [\"22798524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of NOS1-derived NO in the Ca2+-handling apparatus not identified here\", \"Does not distinguish NO vs S-nitrosylation mechanisms\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that NOS1 splice-variant identity dictates the NO-versus-superoxide balance, providing a molecular basis for context-dependent oxidative output.\",\n      \"evidence\": \"EPR measurement of electron uncoupling and 8-nitroguanosine-cGMP detection in HEK293 cells expressing nNOS-\\u03b1 vs nNOS-\\u00b5\",\n      \"pmids\": [\"28126743\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological tissue contexts where each variant predominates not defined\", \"Single-lab in vitro/cell measurements\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified S-nitrosylation of PTEN and mitochondrial NOS1 translocation as a pro-survival mechanism in carcinoma cells, activating AKT/mTOR and limiting autophagy.\",\n      \"evidence\": \"Biotin-switch assay, NOS1 knockdown/inhibition with autophagy-inhibitor rescue and xenografts in nasopharyngeal carcinoma\",\n      \"pmids\": [\"28243469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PTEN S-nitrosylation site(s) not mapped\", \"Single-lab evidence for Hsp90-dependent mitochondrial translocation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established NOS1-mediated S-nitrosylation of HDAC2 as an epigenetic immune-evasion mechanism, linking NO directly to interferon-stimulated gene suppression and metastasis.\",\n      \"evidence\": \"Biotin-switch, ChIP-qPCR, HDAC2-C262A/C274A mutants, and xenograft melanoma models\",\n      \"pmids\": [\"31805977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream regulation of NOS1 activity in melanoma not addressed\", \"Generality across tumor types not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed NOS1-driven tyrosine nitration of TRKB Y816 functions as a molecular brake on neuronal plasticity by triggering receptor endocytosis and degradation.\",\n      \"evidence\": \"In vitro nitration assays, Y816 mutagenesis, endocytosis assays, and ocular dominance plasticity after in vivo nNOS inhibition\",\n      \"pmids\": [\"36682419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic mediator of tyrosine nitration (peroxynitrite vs other) not defined in vivo\", \"Does not address reversibility of TRKB nitration\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended scaffold-disruption logic across multiple CNS pathologies, showing nNOS\\u2013PSD-95 and nNOS\\u2013NOS1AP coupling drive p38 MAPK in TBI, neuropathic pain, thalamic hemorrhage pain, and that PSD-95\\u2013nNOS/TrkB complex switching governs fear extinction.\",\n      \"evidence\": \"Co-IP, disruptor peptides (ZL006, TAT-GESV) and behavioral models in mice/rats\",\n      \"pmids\": [\"31989159\", \"29319606\", \"30193808\", \"30143658\", \"29577585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mostly single-lab Co-IP plus pharmacology without genetic confirmation\", \"Selectivity of disruptor compounds for specific PDZ interactions not exhaustively established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established a renal physiological role, showing collecting-duct NOS1 is required for natriuresis and protection against salt-sensitive hypertension.\",\n      \"evidence\": \"AQP2-Cre conditional NOS1 knockout with dietary sodium challenge and telemetric blood pressure\",\n      \"pmids\": [\"23608660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream tubular targets of NOS1-derived NO not identified\", \"Does not address NOS1 regulation in collecting duct\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the SGLT1\\u2013NOS1 axis at the macula densa, linking luminal glucose sensing through NOS1 Ser1417 phosphorylation to tubuloglomerular feedback and hyperfiltration.\",\n      \"evidence\": \"Macula densa-specific NOS1 knockout, microperfusion/micropuncture, GFR measurement, and SGLT1 inhibition\",\n      \"pmids\": [\"30867247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase mediating Ser1417 phosphorylation downstream of SGLT1 not identified\", \"Translation to human diabetic hyperfiltration not directly tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected NOS1 to insulin-independent cardiac glucose uptake via NO/sGC/PKG-driven GLUT-1 surface density, and to NOS1AP-genotype-dependent arrhythmogenesis through ion-channel regulation.\",\n      \"evidence\": \"CRISPR nNOS knockout in GCH1-Tg mice, glucose uptake assays, and LQT1 patient hiPSC-CMs with guinea pig cardiomyocyte electrophysiology\",\n      \"pmids\": [\"33494625\", \"32061134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which NOS1AP SNPs reduce NOS1 expression/co-localization not fully resolved\", \"Direct ion-channel S-nitrosylation targets not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined sarcolemmal NOS1 localization as a determinant of muscle homeostasis, showing the sarcoglycan complex and biglycan target NOS1 to the membrane and that its sarcoplasmic redistribution drives FoxO3-dependent atrophy.\",\n      \"evidence\": \"Sarcoglycan-deficient and biglycan-null models, biglycan protein injection, unloading models, and in vivo nNOS inhibition with FoxO3 nuclear localization readouts\",\n      \"pmids\": [\"12409321\", \"16807372\", \"30066461\", \"31043586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism translating displaced NOS1 activity into FoxO3 nuclear entry not fully mapped\", \"Role of nNOS\\u2013GSNOR S-nitrosylation homeostasis in atrophy not causally established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified NOS1-expressing interneurons in the nucleus accumbens as drivers of MMP-dependent synaptic potentiation underlying cocaine relapse, defining a discrete circuit role.\",\n      \"evidence\": \"NO-sensitive electrodes, DREADD activation/silencing, caspase ablation, electrophysiology, and reinstatement behavior in rodents\",\n      \"pmids\": [\"28123012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular MMP substrates underlying potentiation not identified\", \"Generalization to other reward circuits not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended NOS1 function to innate immunity and hematopoiesis, showing NO directs AP-1 composition for macrophage polarization and promotes C/EBP\\u03b1-dependent granulopoiesis via G-CSFR\\u2013STAT3.\",\n      \"evidence\": \"Pharmacological NOS1 inhibition in macrophages and in vivo, nNOS overexpression in K562, and human CD34+ HSPC differentiation\",\n      \"pmids\": [\"28013342\", \"33771575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular targets of NO in AP-1 subunit switching not defined\", \"Largely single-lab pharmacological evidence\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established NOS1 as a human disease gene for congenital hypogonadotropic hypogonadism through GnRH neuron dysfunction, with a developmentally timed estrogen-ER\\u03b1 input activating NOS1 during minipuberty and inhaled NO rescuing the phenotype.\",\n      \"evidence\": \"Whole-exome sequencing with mutant activity assays, Nos1-KO phenotyping, time-window NO inhibition/rescue, and ER\\u03b1-blockade with phospho-Ser1412 readouts\",\n      \"pmids\": [\"36197968\", \"36470319\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream NO targets in GnRH neurons not identified\", \"Mechanism of extragonadal estrogen production driving ER\\u03b1 input not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse phosphorylation, scaffolding, splice-variant, and cofactor inputs are integrated to set NOS1's choice between NO, superoxide, and specific S-nitrosylation/nitration targets within a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking variant/cofactor state to target selection\", \"Tissue-specific interactomes not systematically mapped\", \"Reversibility and turnover of nitrosylation/nitration marks largely uncharacterized in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [26, 27, 10]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 6, 7]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [34, 14, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 5, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 9, 22, 34]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [7, 25]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 12, 34]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [2, 14, 31]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 7, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [24, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [27, 21, 3]}\n    ],\n    \"complexes\": [\n      \"dystrophin\\u2013sarcoglycan\\u2013syntrophin complex\",\n      \"nNOS\\u2013PSD-95\\u2013NOS1AP complex\"\n    ],\n    \"partners\": [\n      \"PSD-95\",\n      \"NOS1AP\",\n      \"CAPON\",\n      \"biglycan\",\n      \"GSNOR\",\n      \"HDAC2\",\n      \"PTEN\",\n      \"TRKB\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}